Author

Michael Smyth 1

1 Takeda Development Centre Europe Ltd,London,United Kingdom

A MULTINATIONAL STUDY TO DETERMINE INDICATORS OF SUBOPTIMAL THERAPY AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS

James Lindsay, Javier Gisbert, Reema Mody, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Bernd Bokemeyer, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

CORTICOSTEROID DOSE REDUCTION IN ULCERATIVE COLITIS PATIENTS TREATED WITH VEDOLIZUMAB

Edward V. Loftus Jr., Corey A Siegel, Remo Panaccione, William Sandborn, Michael Smyth, Alexandra Green, Jing Xu, Brihad Abhyankar

CORTICOSTEROID DOSE REDUCTION WITH VEDOLIZUMAB TREATMENT OF CROHN’S DISEASE

Edward V. Loftus Jr., Corey A Siegel, Remo Panaccione, William Sandborn, Michael Smyth, Alexandra Green, Jing Xu, Brihad Abhyankar

COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

Michele Wilson, Matthew Kerrigan, Michael Smyth, Helene Chevrou-Severac, Annika Bergman, Ross Selby

COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH INFLIXIMAB, ADALIMUMAB, AND GOLIMUMAB FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

Michele Wilson, Matthew Kerrigan, Michael Smyth, Annika Bergman, Helene Chevrou-Severac, Ross Selby

INDICATORS OF SUBOPTIMAL THERAPY AMONG CROHN’S DISEASE PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS: RESULTS FROM A MULTINATIONAL STUDY

Alessandro Armuzzi, James Lindsay, Reema Mody, Bernd Bokemeyer, Javier Gisbert, Laurent Peyrin-Biroulet, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

LONG-TERM EFFICACY OF VEDOLIZUMAB THERAPY FOR CROHN’S DISEASE

Stephen B Hanauer, Paul Rutgeerts, David T. Rubin, Michael Smyth, Brihad Abhyankar

LONG-TERM EFFICACY OF VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS

Brian G. Feagan, Arthur Kaser, Michael Smyth, Remo Panaccione, Serap Sankoh, Brihad Abhyankar

PREDICTORS OF NON-RESPONSE OR LOSS OF RESPONSE TO TUMOUR NECROSIS FACTOR ANTAGONIST THERAPIES IN INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet, Alessandro Armuzzi, Javier Gisbert, Geoffrey C. Nguyen, Bernd Bokemeyer, James Lindsay, Michael Smyth, Melvin Munsaka, Sreeram Ramagopalan, Javaria Mona Khalid

REDUCTIONS IN CORTICOSTEROID USE IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE TREATED WITH VEDOLIZUMAB

Bruce E. Sands, Stephen B Hanauer, Jean-Frederic Colombel, Silvio Danese, Terry Ponich, Serap Sankoh, Michael Smyth, Brihad Abhyankar, Irving Fox, Brian G. Feagan, Maria T. Abreu

Item 1 - 10 / 12
1
2